London knowledge economy needs policy backing, UCL argues
London’s innovation districts are becoming more central to the UK growth debate as policymakers weigh how to support high-productivity research clusters beyond traditional regional funding efforts. The argument is that backing the capital’s existing strength in AI, life sciences and fintech can accelerate national growth while reinforcing other city regions rather than displacing them.
Highlights
- UCL argues London should receive government policy support on par with Oxford-Cambridge and Manchester due to its dense innovation cluster including Google DeepMind and the Francis Crick Institute.
- State-backed biomedical research centres in London face funding risks, raising concerns that decentralisation could weaken private investment and innovation-led growth citywide.
- London’s innovation spillovers in AI, life sciences, and fintech underpin UK-wide competitiveness, and UCL warns against thinly spreading funding, risking a fall behind the U.S. and Japan.
Case for backing London’s innovation base
As reported by Financial Times, the case being made is that London should be treated alongside Oxford-Cambridge and Manchester as one of the UK’s most important innovation clusters, rather than being sidelined in efforts to rebalance the economy.The argument rests on the concentration of universities, hospitals, laboratories, investors and businesses in areas such as north London’s Knowledge Quarter, where institutions including Google DeepMind, the Francis Crick Institute, UCL Hospital and the Alan Turing Institute sit in close proximity. That density is presented as a key reason innovation succeeds, because talent attracts companies, companies attract capital and collaboration becomes easier when researchers, clinicians, students and entrepreneurs are physically close.
The article says this kind of critical mass takes decades, even centuries, to build. It points to government support for the Ox-Cam Arc and to Manchester’s growth over the past decade as evidence that ministers already recognise the value of established research-led clusters, and argues London merits the same policy priority.
It also warns that some state-backed biomedical research centres in the capital face funding risk, despite their role in enabling medical breakthroughs. In that view, weakening London’s research base in the name of decentralisation would undermine a proven source of private investment and innovation-led growth.
National spillovers and competitiveness
London is presented as uniquely placed to deliver faster growth because of its role across AI, life sciences, fintech and the cultural and creative industries. Its universities train graduates, attract international talent and support companies whose operations extend well beyond the capital, while research produced in London is said to feed NHS treatments and exports nationwide.One example cited is Autolus Therapeutics, a UCL spinout that is based in London, manufactures in Stevenage and is first delivering its treatments in Manchester. The broader point is that capital raised in London helps finance companies across the country, linking the city’s financial strength to regional industrial development.
The piece argues that stronger innovation hubs should not be seen as competing with smaller cities. Drawing on work from the Bennett Institute on connected clusters, it says regions can reinforce each other through supply chains, skills development, research infrastructure and trade, meaning productivity gains in London can support growth elsewhere in the UK, and vice versa.
The warning for policymakers is that spreading limited funding too thinly may leave every area able to survive but not to scale. In that scenario, the UK risks falling behind countries such as the U.S. and Japan, which have spent decades building world-class innovation centres.
Our earlier coverage of the case for recognising London as a core UK innovation cluster explained why the capital’s dense network of universities, hospitals, labs, investors and startups is seen as a long-built competitive advantage. We also noted warnings that funding risks for state-backed biomedical research centres could weaken breakthroughs and spillovers that support NHS treatments, private investment and growth across the wider UK.